Bristol-Myers Squibb is upgraded to Buy as its growth portfolio now offsets legacy declines, validating a bullish contrarian ...

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced in Q4 CY2025, with sales up 1.4% year on year to $12.5 ...

CHONGQING, CHINA - JULY 29: In this photo illustration, a person holds a smartphone displaying the logo of Bristol Myers Squibb Company (NYSE: BMY), a global biopharmaceutical firm focused on oncology ...

At the end of last year, the company did particularly well with its lineup of newer medications.

Bristol Myers Squibb's financial results haven't been great in recent years. The giant drugmaker has been facing challenges, including several patent cliffs. New launches, pipeline progress, and a ...

Bristol-Myers Squibb (NYSE: BMY) has considerably lagged behind the overall market, with its stock decreasing by 20% this year, while the S&P 500 index has risen by 14%. This drop can be attributed in ...